Theoria Creative ads

He did not say no. He just turned around. The forest had grown too dark to see the way forward. The firefly was right there, holding the answer. The squirrel went back into the woods. A short illustrated story about being overlooked.

Brilliant science. Strong data. No clear way to explain either. The ant needed to be home before sunset. He could not wait to work out what the light was for, so he walked into the dark without it. A short illustrated story about why good companies get overlooked.

Strong science. A willing listener. An explanation that asked too much. The hummingbird needed nectar before the cold night. She stayed. She tried. She only grew tired. A short illustrated story about the difference between attention and understanding.

You've seen this in your work: "strong science + weak story = disappointing outcomes". Investors aren't paying for the mechanism. They're paying for conviction. And when the client's deck does not tell the story, the deal stalls, valuation drops, and the bonuses thin out. Theoria Creative team has the skills and the scientific background to address this issue. We work directly with biotech clients on narrative, deck, and investor materials — so the story does the work it's supposed to do, and your team does the work only bankers can.

Which of your biotech clients has encountered this issue? A weak biotech story doesn't just slow the fundraise. It devalues it. The deal stalls, valuation drops, and the bonuses thin out. Bankers see this earlier than anyone else, and by the time the deck reaches the deal team, fixing it becomes unbillable hours that don't advance the deal. Theoria Creative works with clients before the fundraise — sharpening the narrative, rebuilding the materials, and making the investment case clear. So the story is crafted to build investor conviction.

Your portfolio has strong science. But does it have a compelling story to win the next round? Most biotech companies don't underperform on data. They underperform on narrative. Decks are too technical for investors. Messaging is interchangeable with every other life sciences company at the same stage. Positioning is burying what's differentiated. Theoria Creative works with your portfolio companies ahead of key investor events and BD conversations — translating complex science into investor-ready stories, sharper messaging, and stronger visuals to ensure your portfolio companies succeed this round and next.